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How Was the Hypothesis Tested?
Shea and colleagues 1 chose 2 approaches to fine-map a 250-kb region on chromosome 9p21 that comprises a locus related to myocardial infarction and 2 type 2 diabetes loci. They performed targeted sequencing of the region in 47 HapMap CEU (Centre d'Etude du Polymorphisme Humain, Utah) individuals and used publicly available data from the low-coverage 1000 Genomes Project Pilot 1 phase in 32 overlapping CEU individuals. Resequencing achieved high sensitivity and specificity validated against HapMap and high-coverage data of the 1000 Genomes Project Pilot 2 and through validation genotyping.
Single-nucleotide polymorphisms (SNPs) identified through sequencing were genotyped in an additional 168 CEU individuals and imputed into type 2 diabetes and myocardial infarction case-control studies. Both studies comprised more than 2000 participants of the Diabetes Genetics Initiative and Myocardial Infarction Genetics Consortium cohorts with first-generation GWAS data available. Three samples, the resequenced sample, the additionally genotyped 168 CEU individuals, and 1000 Genomes Pilot 1 individuals served as reference panels for comparison.
Principal Findings
Both resquencing and comparison with 1000 Genomes Project SNPs revealed approximately 4000 SNPs at the loci of interest. Only roughly 75% overlapped, with 1850 SNPs distinct to either method. SNPs solely identified by highcoverage targeted sequencing were rare variants, the majority of them being singletons. Failed target coverage was common in SNPs not found by targeted de novo sequencing but was captured by 1000 Genomes Pilot 1 data.
Imputation results into the disease cohorts varied considerably when comparing the augmented SNP panel and Hap-Map II-based imputation results, with almost twice as many SNPs (464 versus 238 variants) identified. Common SNPs with a minor allele frequency (MAF) of Ͼ5% were only captured in 80%; SNPs with an MAF of 2-5% hardly achieved an imputation quality of r 2 Ն0.8. When increasing the tag SNP density (approximately 1 SNP per 1.5 kb), common variants were well captured and intermediate frequency SNPs reached good imputation quality in 75%, independent of the GWAS assay used.
Imputation from the predefined reference panels into the disease cohorts revealed comparable proportions of missingness due to genotyping assay failure (genotyped sample), missing coverage (resequencing sample), low coverage (1000 Genomes Pilot 1), and sample size (1000 Genomes and resequencing samples), resulting in distinct SNP panels with good imputation quality. For common SNPs, performance was similar across the reference panels. Imputation in intermediate frequency SNPs performed best for the genotyping panel and was markedly less accurate in the 1000 Genomes Pilot 1 data set.
Variants from all 3 panels were related to disease phenotypes, with approximately 92% of common variation and about half of the intermediate frequency SNPs imputed with good quality. Novel variants almost tripled the number previously imputed from HapMap.
The authors identified new variants in linkage disequilibrium with loci reported in prior publications. No stronger SNP association with disease than for known variants was observed.
Implications
In many first-generation GWAS investigations, the top hit does not appear to represent the causal variant. Therefore, a consequent step for most GWAS results for common SNPs is the fine mapping of the region that produced the initial signal because less frequent or rare variants may be in linkage disequilibrium with the originally identified SNP. For efficient functional follow-up of GWAS findings, the exact identification of the genetic polymorphism responsible for the association is desirable. The fine structure of the human genome is increasingly accessible through next-generation sequencing and the availability of sequencing data sets such as produced by the 1000 Genomes Project and public deposition of sequencing data as provided by the current study (US National Center for Biotechnology Information Short Read Archive).
The investigation by Shea et al demonstrates that highcoverage targeted sequencing and low-coverage 1000 Genomes Pilot 1 data provide distinct sets of SNPs only partially overlapping due to frequency distribution and target coverage. Common genetic polymorphisms with a frequency of Ͼ5% were comparably well imputed into disease cohorts by 3 reference panels (high-coverage targeted sequencing, a larger genotyped sample based on the targeted sequencing variants, and 1000 Genomes Pilot 1 data). In particular, publicly available 1000 Genomes first-release data performed equivalently well compared with cost-and time-intensive targeted sequencing. Nevertheless, for less frequent variants, the 1000 Genomes Pilot 1 data set still is less complete and accurate, where targeted sequencing is of advantage. The latter, however, may be limited by significant gaps in coverage, and a genotyped reference sample appeared to provide most accurate information.
The attempt to find novel genetic variants with stronger disease-phenotype associations at the chromosome 9p21 locus than those reported from GWAS to date was disappointing in this first investigation with a small cohort size and a limited number of sequenced samples. However, more detailed information on associated variants and new SNPs with putative functionality could be detected. In the future, these novel variants may, separately or in combination, contribute to the understanding of the pathophysiological background of the observed associations. Subsequent data sets such as the next phase of the 1000 Genomes Project promise high-quality and ever more refined genetic variation information on exome and whole-genome bases. At present, applying different approaches for fine-mapping provides complementary information. The most comprehensive picture of genetic variation at a certain locus is achieved through the combination of several methods and the exploitation of existing data.
